Search Within

Malin Lisa Hultcrantz

Formats
  1. Meeting Abstract (171)
  2. Journal Article (68)
  3. Research Letter (9)
  4. Guidelines (6)
  5. Review (3)
  6. Correspondence (2)
  7. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (260)
  2. Department of Medicine (260)
  3. Hematologic Malignancies, Division of (260)
  4. Myeloma (260)
  5. Sloan Kettering Institute Postdocs (260)
  6. Hematologic Malignancies Research (179)

More Groups

People
  1. Sham Mailankody (148)
  2. Neha Korde (145)
  3. Alexander Lesokhin (140)
  4. Hani Hassoun (135)
  5. Urvi Shah (125)
  6. Heather Landau (119)

More People

Years
  1. 2025 (8)
  2. 2024 (39)
  3. 2023 (51)
  4. 2022 (52)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (50)
  3. Journal of Clinical Oncology (17)
  4. Blood Cancer Journal (13)
  5. Haematologica (10)
  6. Blood Advances (6)

More Publications

Publishers
  1. American Society of Hematology (103)
  2. Elsevier Inc. (55)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (10)
  6. American Association for Cancer Research (6)

More Publishers

Results (260)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Revealing the impact of structural variants in multiple myeloma
    Journal Article

    Rustad, E. H.; Yellapantula, V. D.; Glodzik, D.; Maclachlan, K. H.; Diamond, B.; Boyle, E. M.; Ashby, C.; Blaney, P.; Gundem, G.; Hultcrantz, M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers
    Journal Article

    Hultcrantz, M.; Richter, J.; Rosenbaum, C. A.; Patel, D.; Smith, E. L.; Korde, N.; Lu, S. X.; Mailankody, S.; Shah, U. A.; Lesokhin, A. M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Infusion-related reactions (IRRs) in the DREAMM-2 Study of single-agent belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nooka, A.; Lee, H. C.; Badros, A. Z.; Voorhees, P.; Hultcrantz, M.; Karlin, L.; Arnulf, B.; Richardson, P. G.; Zhi, E.; Baron, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: Progressive versus stable myeloma precursor disease
    Meeting Abstract

    Oben, B.; Froyen, G.; Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Abascal, F.; Leongamornlert, D. A.; Derkach, A.; Geerdens, E.; Diamond, B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save